2 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
Follow Jennifer Crombie, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembro Plus CAR T-cell Therapy in R/R in PMBCL Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion - Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma | Phase 2 | Recruiting | Jennifer Crombie, MD | 35 | 2023-11-15 | 2026-03-05 |
| A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma Glofitamab, Polatuzumab, Rituximab - Lymphoma, Lymphoma, Large B-Cell, Diffuse | Phase 2 | Recruiting | Jennifer Crombie, MD | 41 | 2023-04-06 | 2026-03-05 |
Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1)
Cyclophosphamide (2) · Automobiles (1) · Doxorubicin (1) · Leukapheresis (1) · Methylprednisolone (1) · Prednisolone (1) · Prednisone (1) · Receptors, Chimeric Antigen (1) · Rituximab (1) · fludarabine (1) · glofitamab (1) · pembrolizumab (1) · polatuzumab vedotin (1)
United States (2)